Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors

NCT01693562 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT01693562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01693562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors
Lead sponsor
MedImmune LLC
Phase
Phase 1/2
Overall status
Completed
Start date
September 5, 2012
Completion date
February 28, 2020
Enrollment
1,022 (actual)
Sites
79

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors